Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;36(5):820-832.
doi: 10.1002/jbmr.4235. Epub 2021 Feb 8.

Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis

Danielle E Robinson  1 , M Sanni Ali  1   2   3 , Natalia Pallares  4 , Cristian Tebé  4   5 , Leena Elhussein  1 , Bo Abrahamsen  6   7   8 , Nigel K Arden  9 , Yoav Ben-Shlomo  10 , Fergus J Caskey  10   11 , Cyrus Cooper  6   12 , Daniel Dedman  13 , Antonella Delmestri  1 , Andrew Judge  1   12   14 , María José Pérez-Sáez  15 , Julio Pascual  15 , Xavier Nogues  16   17 , Adolfo Diez-Perez  16 , Victoria Y Strauss  1 , M Kassim Javaid  6 , Daniel Prieto-Alhambra  1   18
Affiliations
Free article

Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis

Danielle E Robinson et al. J Bone Miner Res. 2021 May.
Free article

Abstract

Bisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic kidney disease (CKD) patients, primarily because of a lack of information about their safety and effectiveness. We aimed to investigate the safety of oral bisphosphonates in patients with moderate to severe CKD, using primary-care electronic records from two cohorts, CPRD GOLD (1997-2016) and SIDIAP (2007-2015) in the UK and Catalonia, respectively. Both databases were linked to hospital records. SIDIAP was also linked to end-stage renal disease registry data. Patients with CKD stages 3b to 5, based on two or more estimated glomerular filtration rate measurements less than 45 mL/min/1.73 m2 , aged 40 years or older were identified. New bisphosphonate users were propensity score-matched with up to five non-users to minimize confounding within this population. Our primary outcome was CKD stage worsening (estimated glomerular filtration rate [eGFR] decline or renal replacement therapy). Secondary outcomes were acute kidney injury, gastrointestinal bleeding/ulcers, and severe hypocalcemia. Hazard ratios (HRs) were estimated using Cox regression and Fine and Gray sub-HRs were calculated for competing risks. We matched 2447 bisphosphonate users with 8931 non-users from CPRD and 1399 users with 6547 non-users from SIDIAP. Bisphosphonate use was associated with greater risk of CKD progression in CPRD (sub-HR [95% CI]: 1.14 [1.04, 1.26]) and SIDIAP (sub-HR: 1.15 [1.04, 1.27]). No risk differences were found for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcemia. Hence, we can conclude a modest (15%) increased risk of CKD progression was identified in association with bisphosphonate use. No other safety concerns were identified. Our findings should be considered before prescribing bisphosphonates to patients with moderate to severe CKD. © 2020 American Society for Bone and Mineral Research (ASBMR).

Keywords: ANTIRESORPTIVES; FRACTURE PREVENTION; GENERAL POPULATION STUDIES; OSTEOPOROSIS; STATISTICAL METHODS.

PubMed Disclaimer

Comment in

References

    1. Kerr M. Chronic kidney disease in England: the human and financial cost. London: NHS Kidney Care; 2017.
    1. Otero González A, De Francisco A, Gayoso P, García F, EPIRCE Study Group. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78-86.
    1. Pan B-L, Loke S-S. Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome. PLoS One. 2018;13(1):e0190985.
    1. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32.
    1. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167(2):133-9.

Publication types

MeSH terms